Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06467084 · ClinicalTrials.gov registry record · Phase 3
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
A Phase 3 study, sponsored by KalVista Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
NCT06467084 is a Phase 3 study that has completed, run by KalVista Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT06467084, a Phase 3 study, has completed, sponsored by KalVista Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
Study Summary
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Interventions
- DRUG KVD900 600 mg
- DRUG KVD900 300 mg
- DRUG KVD900 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2026-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06467084
The ClinicalTrials.gov registry entry for NCT06467084 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which KVD900 600 mg is the first listed.
NCT06467084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06467084 about?
NCT06467084 is a clinical study titled "Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II". KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
What is the current status of trial NCT06467084?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2024-06-24. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT06467084?
The interventions under investigation include: KVD900 600 mg (DRUG), KVD900 300 mg (DRUG), KVD900 150 mg (DRUG).
Who is sponsoring clinical trial NCT06467084?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.